KIF2C and pancreatic adenocarcinoma: Interestingly, 1.8% of all patients in the TCGA cohort including PAAD (Pancreatic Adenocarcinoma) had genetic alterations in the KIF2C gene, which included predominantly missense mutations or amplifications [95].